WO2007118819A3 - Neue kristalline verbindungen - Google Patents

Neue kristalline verbindungen Download PDF

Info

Publication number
WO2007118819A3
WO2007118819A3 PCT/EP2007/053488 EP2007053488W WO2007118819A3 WO 2007118819 A3 WO2007118819 A3 WO 2007118819A3 EP 2007053488 W EP2007053488 W EP 2007053488W WO 2007118819 A3 WO2007118819 A3 WO 2007118819A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
crystalline compounds
novel crystalline
naphthalene
acids
Prior art date
Application number
PCT/EP2007/053488
Other languages
English (en)
French (fr)
Other versions
WO2007118819A2 (de
Inventor
Uwe Ries
Sonja Sproll
Ulrike Werthmann
Andreas Zopf
Guenther Huchler
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Pharma
Uwe Ries
Sonja Sproll
Ulrike Werthmann
Andreas Zopf
Guenther Huchler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, Uwe Ries, Sonja Sproll, Ulrike Werthmann, Andreas Zopf, Guenther Huchler filed Critical Boehringer Ingelheim Int
Priority to CA002648140A priority Critical patent/CA2648140A1/en
Priority to JP2009504732A priority patent/JP2009533387A/ja
Priority to MX2008013158A priority patent/MX2008013158A/es
Priority to EP07727956A priority patent/EP2010513A2/de
Priority to AU2007239505A priority patent/AU2007239505A1/en
Priority to BRPI0710151-1A priority patent/BRPI0710151A2/pt
Priority to EA200802049A priority patent/EA200802049A1/ru
Publication of WO2007118819A2 publication Critical patent/WO2007118819A2/de
Publication of WO2007118819A3 publication Critical patent/WO2007118819A3/de
Priority to NO20083709A priority patent/NO20083709L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

Die vorliegende Erfindung betrifft die neuen kristallinen Verbindungen A der allgemeinen Formel (I), in der A1, A2, A3, X, Y1, Y2 und Y3 wie in Anspruch 1 definiert sind, und die in Form ihrer physiologisch verträglichen Salze mit Säuren vorliegen, wobei die Säuren ausgewählt sind aus der Gruppe B bestehend aus Chlorwasserstoffsäure, Bromwasserstoffsäure, Schwefelsäure, Phosphorsäure, Benzolsulfonsäure, p-Toluolsulfonsäure, Maleinsäure, Bernsteinsäure, Fumarsäure, D-(-)-Weinsäure, L-(+)-Weinsäure, Naphthalin-2-sulfonsäure und Naphthalin-1,5-disulfonsäure, sowie den Polymorphen, den entsprechenden Solvaten und Hydraten.
PCT/EP2007/053488 2006-04-13 2007-04-11 Neue kristalline verbindungen WO2007118819A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002648140A CA2648140A1 (en) 2006-04-13 2007-04-11 New crystalline compounds
JP2009504732A JP2009533387A (ja) 2006-04-13 2007-04-11 新規結晶性化合物
MX2008013158A MX2008013158A (es) 2006-04-13 2007-04-11 Nuevos compuestos cristalinos.
EP07727956A EP2010513A2 (de) 2006-04-13 2007-04-11 Neue kristalline verbindungen
AU2007239505A AU2007239505A1 (en) 2006-04-13 2007-04-11 Novel crystalline compounds
BRPI0710151-1A BRPI0710151A2 (pt) 2006-04-13 2007-04-11 compostos cristalinos
EA200802049A EA200802049A1 (ru) 2006-04-13 2007-04-11 Новые кристаллические соединения
NO20083709A NO20083709L (no) 2006-04-13 2008-08-28 Nye krystallinske forbindelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006017827A DE102006017827A1 (de) 2006-04-13 2006-04-13 Neue kristalline Verbindungen
DE102006017827.0 2006-04-13

Publications (2)

Publication Number Publication Date
WO2007118819A2 WO2007118819A2 (de) 2007-10-25
WO2007118819A3 true WO2007118819A3 (de) 2008-05-29

Family

ID=38514672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/053488 WO2007118819A2 (de) 2006-04-13 2007-04-11 Neue kristalline verbindungen

Country Status (20)

Country Link
US (1) US7638625B2 (de)
EP (1) EP2010513A2 (de)
JP (1) JP2009533387A (de)
KR (1) KR20090007428A (de)
CN (1) CN101421263A (de)
AR (1) AR060442A1 (de)
AU (1) AU2007239505A1 (de)
BR (1) BRPI0710151A2 (de)
CA (1) CA2648140A1 (de)
CO (1) CO6140057A2 (de)
DE (1) DE102006017827A1 (de)
EA (1) EA200802049A1 (de)
EC (1) ECSP088737A (de)
MX (1) MX2008013158A (de)
NO (1) NO20083709L (de)
PE (1) PE20080735A1 (de)
TW (1) TW200808767A (de)
UY (1) UY30280A1 (de)
WO (1) WO2007118819A2 (de)
ZA (1) ZA200806859B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491717B2 (en) * 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2008015562A (es) * 2006-06-08 2008-12-17 Boehringer Ingelheim Int Tratamiento de trastornos gastrointestinales con antagonistas de cgrp.
BR112014021032B1 (pt) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company Sal hemissulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluoro-fenil)-6,7,8,9-tetra-hidro-5h- iclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il}-piperidina-1-carboxilato, seu uso e composição farmacêutica que o compreende

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011128A1 (de) * 1996-09-10 1998-03-19 Dr. Karl Thomae Gmbh Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO2004037810A1 (de) * 2002-10-25 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2004037811A1 (de) * 2002-10-25 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2005092880A1 (de) * 2004-03-29 2005-10-06 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011128A1 (de) * 1996-09-10 1998-03-19 Dr. Karl Thomae Gmbh Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO2004037810A1 (de) * 2002-10-25 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2004037811A1 (de) * 2002-10-25 2004-05-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2005092880A1 (de) * 2004-03-29 2005-10-06 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAIRA, M. R.: "CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS", TOPICS IN CURRENT CHEMISTRY, SPRINGER, BERLIN, DE, vol. 198, 1998, pages 163 - 208, XP001156954, ISSN: 0340-1022 *
See also references of EP2010513A2 *

Also Published As

Publication number Publication date
EP2010513A2 (de) 2009-01-07
JP2009533387A (ja) 2009-09-17
DE102006017827A1 (de) 2007-10-18
ECSP088737A (es) 2008-10-31
EA200802049A1 (ru) 2009-04-28
US7638625B2 (en) 2009-12-29
AU2007239505A1 (en) 2007-10-25
CA2648140A1 (en) 2007-10-25
WO2007118819A2 (de) 2007-10-25
NO20083709L (no) 2008-10-31
MX2008013158A (es) 2008-10-22
BRPI0710151A2 (pt) 2011-08-02
ZA200806859B (en) 2009-08-26
US20080086003A1 (en) 2008-04-10
UY30280A1 (es) 2007-11-30
KR20090007428A (ko) 2009-01-16
TW200808767A (en) 2008-02-16
CO6140057A2 (es) 2010-03-19
CN101421263A (zh) 2009-04-29
PE20080735A1 (es) 2008-07-25
AR060442A1 (es) 2008-06-18

Similar Documents

Publication Publication Date Title
WO2008065681A3 (en) Process for preparation of ivabradine hydrochloride
WO2010070667A3 (en) Process and intermediates for the preparation of 7-( (3-chloro-6-methyl-5,5-dioxo-6,ll-dihydrodibenzo (c, f) (1,2) thiazepin-11-yd amino) heptanoate
GEP20125491B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2008146308A3 (en) Process for the preparation of ivabradine hydrochloride and polymorph thereof
WO2007017728A3 (en) Novel heterocyclic compounds
SG10201407913UA (en) Crystalline freebase forms of a biphenyl compound
WO2010076810A3 (en) A process for the preparation of gefitinib
WO2007118819A3 (de) Neue kristalline verbindungen
WO2008059521A3 (en) Novel process for the preparation of moxifloxacin hydrochloride and a novel polymorph of moxifloxacin
WO2011016052A3 (en) Process for preparing pregabalin
WO2009057140A3 (en) Improved process for memantine hydrochloride
WO2010059503A3 (en) PROCESS FOR MAKING (R) -3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF
WO2007054969A3 (en) Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride
WO2008054690A3 (en) Polymorphs of a hydroisoindoline tachykinin receptor antagonist
WO2007004041A3 (en) New compounds and their pharmaceutical use
WO2006070285A3 (en) Enzymatic preparation of an intermediate compound for the synthesis of tamsulosin
WO2009060297A3 (en) An improved process for the preparation of paliperidone and its intermediates
WO2008015133A3 (en) Process for preparing amidrazones
WO2009129259A3 (en) Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
WO2008007391A3 (en) An improved process for the preparation of valsartan
WO2010122580A3 (en) Piperidine derivatives as inhibitors of renin
WO2007102074A3 (en) Salts of quetiapine
WO2007135693A3 (en) Intermediates useful for the preparation of antihistaminic piperidine derivative
WO2006010511A8 (de) Verfahren zur herstellung 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1h)-on
WO2008099418A3 (en) An improved process for preparing bupropion hydrochloride

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07727956

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007727956

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007239505

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 571334

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2007239505

Country of ref document: AU

Date of ref document: 20070411

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2648140

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 194592

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200780012808.X

Country of ref document: CN

Ref document number: 2008101665

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2009504732

Country of ref document: JP

Ref document number: 12008502276

Country of ref document: PH

Ref document number: 08108825

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013158

Country of ref document: MX

Ref document number: 8558/DELNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027714

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200802049

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0710151

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081010